– Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide – Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, is seeking people who stutter to … Read more
– Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs– Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical … Read more
– Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners – Chicago, March 23, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, today … Read more
– Speak Freely Study Investigates Ecopipam for Childhood-Onset Fluency Disorder – Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been … Read more
– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous … Read more